Overview Performance Dividends Peer Group Options

(ABT) Abbott Laboratories - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0028241000

ABT: Pharmaceuticals, Diagnostics, Nutrition, Devices

Abbott Laboratories (NYSE:ABT) is a global health care leader that discovers, develops, manufactures, and markets a wide range of medical products and solutions. The company operates through four core segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceuticals segment offers generic and branded medications for various therapeutic areas, including gastrointestinal health, cardiovascular diseases, infectious diseases, and central nervous system disorders. The Diagnostic Products segment provides advanced testing systems for clinical chemistry, immunoassay, hematology, and molecular diagnostics, enabling precise and rapid detection of diseases. The Nutritional Products segment includes infant formula and adult nutrition products designed to meet specific dietary needs. The Medical Devices segment focuses on cardiovascular and neuromodulation devices, offering solutions for heart rhythm management, structural heart conditions, and chronic pain.

Abbott Laboratories has a strong track record of innovation, with a portfolio that includes products like FreeStyle Libre for diabetes management, MitraClip for heart failure treatment, and ID NOW for rapid molecular diagnostics. The company was founded in 1888 and is headquartered in North Chicago, Illinois. Abbott is known for its commitment to improving global health, with a presence in over 160 countries and a workforce of approximately 113,000 employees. In 2022, Abbott generated over $43 billion in revenue, underscoring its significant role in the global healthcare industry.

Abbott Laboratories is listed on the NYSE under the ticker symbol ABT. The company is classified under the GICS Sub Industry category of Health Care Equipment. Abbotts market capitalization exceeds $220 billion, reflecting its strong financial position and investor confidence. The stock is widely followed by analysts and investors due to its consistent performance and dividend yield.

Based on and , Abbott Laboratories (ABT) is expected to maintain its upward momentum in the next three months. The stock is trading above its 20-day and 50-day moving averages, with the 200-day moving average providing long-term support. The average true range (ATR) of 3.63 indicates moderate volatility. Fundamentally, the companys strong return on equity (RoE) of 28.12% and a forward P/E ratio of 24.63 suggest continued growth in earnings. The stock is projected to test resistance levels near 140.0, with potential pullbacks finding support at 126.3 and 115.2. Investors should monitor earnings reports, product launches, and macroeconomic trends for further guidance.

Additional Sources for ABT Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

ABT Stock Overview

Market Cap in USD 227,161m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Equipment
IPO / Inception 1978-01-13

ABT Stock Ratings

Growth Rating 42.6
Fundamental 56.4
Dividend Rating 64.2
Rel. Strength 22.7
Analysts 4.26/5
Fair Price Momentum 128.18 USD
Fair Price DCF 80.49 USD

ABT Dividends

Dividend Yield 12m 1.89%
Yield on Cost 5y 2.62%
Annual Growth 5y 8.85%
Payout Consistency 96.6%

ABT Growth Ratios

Growth Correlation 3m -22.5%
Growth Correlation 12m 89.6%
Growth Correlation 5y 30.1%
CAGR 5y 8.18%
CAGR/Max DD 5y 0.24
Sharpe Ratio 12m 0.36
Alpha 16.83
Beta 0.301
Volatility 25.31%
Current Volume 4849k
Average Volume 20d 7998.2k
What is the price of ABT stocks?
As of April 27, 2025, the stock is trading at USD 128.85 with a total of 4,849,045 shares traded.
Over the past week, the price has changed by -0.80%, over one month by +3.06%, over three months by +0.01% and over the past year by +23.00%.
Is Abbott Laboratories a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Abbott Laboratories (NYSE:ABT) is currently (April 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 56.39 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ABT as of April 2025 is 128.18. This means that ABT is currently overvalued and has a potential downside of -0.52%.
Is ABT a buy, sell or hold?
Abbott Laboratories has received a consensus analysts rating of 4.26. Therefor, it is recommend to buy ABT.
  • Strong Buy: 13
  • Buy: 8
  • Hold: 6
  • Sell: 0
  • Strong Sell: 0
What are the forecast for ABT stock price target?
According to ValueRays Forecast Model, ABT Abbott Laboratories will be worth about 139.2 in April 2026. The stock is currently trading at 128.85. This means that the stock has a potential upside of +8.01%.
Issuer Forecast Upside
Wallstreet Target Price 140.9 9.3%
Analysts Target Price 130.6 1.4%
ValueRay Target Price 139.2 8%